Clinical trial · Observational
Survey on the Treatment Reality of Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Non-small Cell Lung Cancer(NSCLC)
Survey on the Treatment Reality of Patients With EGFR Mutation-positive Non-small Cell Lung Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
According to the recent report using EGFR tyrosine kinase inhibitors (EGFR-TKI), there is all over survival of the EGFR gene mutation-positive NSCLC in a tendency to extension. However, the real situation and the reason are not clarified.This observational study collects the data of EGFR gene mutation-positive NSCLC approximately 2,000 from the medical record of approximately 20 facilities in Japan and observes the treatment reality of EGFR gene mutation-positive NSCLC.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Non-Small-Cell Lung | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Overall survival of the patients.
- timeFrame
- Up to 3 monthes. Data will be collected retrospectively from medical records.Survival status as of the end of December 2014, date of death or date of last follow-up of survival.
Secondary outcomes (4)
- measure
- Overall survival by patient background
- timeFrame
- Up to 3 monthes. Data will be collected retrospectively from medical records.
- measure
- Overall survival by treatment sequence
- timeFrame
- Up to 3 monthes. Data will be collected retrospectively from medical records.
- measure
- Treatment time by treatment category
- timeFrame
- Up to 3 monthes. Data will be collected retrospectively from medical records.
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * 1\. EGFR mutation-positive progress recurrent non-small cell lung cancer subject. * 2\. Subjects who commenced on first-line treatment between January, 2008 and December 2012. Exclusion Criteria: * 1\. Patients has a treatment history with the drug which was not approved for marketing authorization as of 31th December , 2014 * 2\. Person who were planning and/or getting involved in this survey. (applies to both AstraZeneca staff and/or staff at the study site) * 3\. Previous enrolment in the present study. * 4\. Patient was not evaluated to be appropriate for study enrolment by the investigators
References
Publications (0)
Data not yet available